ЦИСТАТИН-С КАК МАРКЕР РАННЕЙ ПОЧЕЧНОЙ ДИСФУНКЦИИ ПРИ КОМОРБИДНОСТИ ХОБЛ И ХСН
Keywords:
ХОБЛ; ХСН; цистатин-С; рСКФ; хроническая болезнь почек; коллаген IV типа; нефросклероз; кардиоренальный синдром; дапаглифлозин; нефропротекция.Abstract
оценить динамику цистатина-С и расчётной скорости клубочковой фильтрации (рСКФ) в зависимости от степени тяжести ХОБЛ при коморбидности с ХСН, а также изучить диагностическую значимость цистатина-С в сравнении с сывороточным креатинином для выявления ранней почечной дисфункции.
References
Axson EL, Ragutheeswaran K, Sundaram V et al. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res. 2020;21(1):54.
Ruvuna L, Sood A. Epidemiology of Chronic Obstructive Pulmonary Disease. Clin Chest Med. 2020;41(3):315–327.
McCullough PA, Kellum JA, Haase M et al. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the ADQI. Contrib Nephrol. 2013;182:82–98.
Веснина Ж.В., Арсеньева Ю.А. Кардиоренальный синдром: современные взгляды на проблему. Клиническая медицина. 2012;7:8–13.
Inker LA, Schmid CH, Tighiouart H et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29.
Shlipak MG, Sarnak MJ, Katz R et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049–2060.
Peralta CA, Shlipak MG, Judd S et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305(15):1545–1552.
Van J, Scholey J, Konvalinka A. Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics. J Am Soc Nephrol. 2017;28(4):1050–1061.
Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012;1:89–115.
Rangaswami J, Bhalla V, Blair JEA et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies. Circulation. 2019;139(16):e840–e878.
Ronco C, Haapio M, House AA et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–1539.
Helal I, Fick-Brosnahan G, Reed-Gitomer B et al. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012;8(5):293–300.
McMurray JJV, Solomon SD, Inzucchi SE et al. (DAPA-HF). Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
Wu JY, Hu KC, Liu MY et al. The clinical effectiveness of SGLT2 inhibitors on prognosis of patients with COPD and diabetes. Nat Commun. 2025;16(1):5478.
Heerspink HJL, Stefánsson BV, Correa-Rotter R et al. (DAPA-CKD). Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in IQRO — Scientific Methodological Journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Authors retain copyright and grant the journal the right of first publication.
Users may read, download, copy, distribute, print, search, or link to the full texts of articles, provided that the original authors and the journal are properly cited.
Published materials may be used, distributed, and reproduced in any medium, provided that the original work is properly cited.



Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo